Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02239614
Other study ID # S-13-10
Secondary ID ADVP-003WRAIR #2
Status Completed
Phase Phase 1
First received
Last updated
Start date December 2014
Est. completion date February 17, 2017

Study information

Verified date August 2018
Source U.S. Army Medical Research and Materiel Command
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with alum and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date February 17, 2017
Est. primary completion date February 17, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

1. Male or female between 18 and 49 years of age (inclusive) at the time of consent

2. Able to provide written informed consent

3. Healthy as established by medical history and clinical examination before entering into the study

4. Able and willing to comply with the requirements of the protocol (eg, document events in memory aid, return for follow-up visits, etc.)

5. Female subject of non-childbearing potential (non-childbearing potential is defined as having either a current tubal ligation at least 3 months prior to enrollment or a history of a hysterectomy, ovariectomy, or is post-menopause)

6. Female subject is not breastfeeding and agrees not to breastfeed for 3 months after last vaccination

7. Female subject of childbearing potential may be enrolled in the study, if the subject has:

1. Practiced adequate contraception for 30 days prior to vaccinations, and

2. A negative urine pregnancy test on each day of vaccination, and

3. Agreed to continue adequate contraception until 3 months after completion of the vaccination series.

Exclusion Criteria:

1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the period starting 30 days preceding the first dose of study vaccine and/or planned use during the study period

2. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose

1. For corticosteroids, this will mean prednisone = 20 mg/d or equivalent

2. Inhaled and topical steroids are allowed

3. Planned administration or administration of a vaccine/product not foreseen by the study protocol during the period starting 14 days before or after each scheduled dose of an investigational product

4. Planned administration of any flavivirus vaccine for the entire study duration

5. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)

6. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)

7. Family history of congenital or hereditary immunodeficiency

8. History of, or current, auto-immune disease

9. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or related to a study procedure

10. Major congenital defects or serious chronic illness

11. History of any neurological disorders or seizures. (except for a childhood febrile seizures)

12. Acute disease and/or fever (oral body temperature = 100.4°F/38.0°C) at the time of enrollment (a subject with a minor illness, ie, mild diarrhea, mild upper respiratory infection, etc, without fever, may be enrolled at the discretion of the investigator)

13. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests

14. Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine or planned administration during the study period

15. History of chronic alcohol and/or drug abuse

16. Pregnant or breastfeeding female or female planning to become pregnant or planning to discontinue contraceptive precautions

17. A planned move to a location that will prohibit participating in the trial prior to the study end for the participant

18. Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)

19. Safety laboratory test results that are outside the acceptable values at screening:

1. > 110% upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, serum urea nitrogen (SUN) and bilirubin (total and direct)

2. < 100% lower limit of normal (LLN) or > 120% ULN for hemoglobin, hematocrit and platelet count

3. < 75% LLN or >110% ULN for total white blood cell count (WBC)

20. Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
TDENV-LAV
0.5 mL of the post-transfection LAV F17 vaccine
TDENV-PIV 4 µg + alum adjuvant
0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant

Locations

Country Name City State
United States Clinical Trials Center, Walter Reed Army Institute of Research (CTC, WRAIR) Silver Spring Maryland

Sponsors (1)

Lead Sponsor Collaborator
U.S. Army Medical Research and Materiel Command

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of solicited adverse events 21 days after each vaccination
Primary Number of unsolicited adverse events 28 days after each vaccination
Primary Number of hematological and biochemistry abnormalities 7 and 28 days and each vaccination
Primary Number of serious adverse events Day 208 or day 360
Primary Number of potential immune-mediated diseases Day 208 or day 360
Primary Number of medically attended adverse events Day 208 or day 360
Secondary Microneutralizing (MN) dengue antibody titers Up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1